The coronavirus pandemic fostered and underscored the benefits of public-private partnerships as healthcare supply chain companies used their expertise and strengths to support the government’s response to an ongoing health crisis. The Milken Institute’s “2021 Partnering for Patients Forum” explored this topic during a panel discussion entitled, “Reimagining Public Health Partnerships: Lessons Learned from the Pandemic.”
Events spanning COVID-19 vaccine distribution to shipping containers held up at port have made the supply chain a “kitchen-table” issue during the past year. Many industries experienced notable disruptions in their delivery of goods and supplies; however, as noted by President and CEO Chip Davis, “[P]harmacies, health systems and physicians’ offices, more than 180,000 across the country, remain stocked with the lifesaving medications and vaccines patients need. That didn’t happen by accident.” Davis’ perspective was featured alongside healthcare supply chain association leaders as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.
The two-year countdown to the Drug Supply Chain Security Act (DSCSA) deadline has begun. This final milestone, in combination with those already completed, will fundamentally change how product and data move together across the healthcare supply chain.
On October 7, HDA launched a three-part series to showcase how the distribution industry is helping create healthier communities through philanthropy, employee activism, partnerships with nonprofit organizations and more.